Tsuyoshi Muta

Tsuyoshi Muta

Auto-generated profile, based on publicly available information

Tsuyoshi Muta

Department of Hematology/Oncology, Japan Community Health Care Organization (JCHO) Kyushu Hospital, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in European Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
KMKenichi Miyako
Kenichi Miyako
TITakashi Irie
Takashi Irie
TMTsuyoshi Muta
Tsuyoshi Muta
SUShuyo Umeda
Shuyo Umeda
YKYoichiro Kai
Yoichiro Kai
DKDongchon Kang
Dongchon Kang
1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine is known to cause Parkinsonism in its neurotoxic form, 1‐methyl‐4‐phenylpyridinium ion (MPP+). We have previously reported that MPP+ decreases the content of mitochondrial DNA (mtDNA) independently of the inhibition of complex I in human cells [Miyako, K., Kai, Y., Irie, T., Takeshige, K., and Kang, D. (1997) J. Biol. Chem.272, 9605–9608]. Here we study the mechanism causing the decrease in mtDNA. MPP+ inhibits the incorporation of 5‐bromo‐2′‐deoxyuridine into mtDNA but not into nuclear DNA, indicating that MPP+ inhibits the replication of mtDNA but not that of the nuclear genome. The replication of mtDNA is initiated by the synthesis of the heavy strand switched from the transcription of the light strand. MPP+ decreases the nascent heavy strands per mtDNA and increases the transcript of the ND6 gene, encoded on light strand, per mtDNA. The amount of mitochondrial transcription factor A is not decreased. These data suggest that the transcription is not inhibited and therefore the transition from transcription to replication of mtDNA is lowered in the MPP+‐treated cells. Electron microscopy shows that the number of mitochondria is not decreased in the MPP+‐treated cells, suggesting that MPP+ does not affect the overall biogenesis of mitochondria. Thus, MPP+ selectively inhibits the replication of mtDNA.

17 January 2018 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
TMTsuyoshi Muta
Tsuyoshi Muta
TMToshihiro Miyamoto
Toshihiro Miyamoto
TKTomohiko Kamimura
Tomohiko Kamimura
YKYoshinobu Kanda
Yoshinobu Kanda
MNMasaharu Nohgawa
Masaharu Nohgawa
KSKazutaka Sunami
Kazutaka Sunami
Autologous stem cell transplantation (ASCT) has been employed for patients with relapsed multiple myeloma (MM) after up-front ASCT. The present retrospective study aimed to examine the survival benefit from salvage ASCT. Among 446 patients with relapsed MM after up-front single ASCT, 70 patients received salvage ASCT, the employment of which reduced the risk of mortality after relapse (p = 0.041). Using the parameters before initial ASCT, the advantage of salvage ASCT compared to standard therapy was confirmed in the subgroup with an international staging system stage of I or II (p = 0.040), good performance status (PS; p = 0.043), or no/mild renal comorbidity (p = 0.029). The advantage of salvage ASCT was also confirmed in the subgroup excluding those with early relapse within 7 months after initial ASCT (p = 0.026). Among patients who received salvage ASCT, a favorable prognosis is apparent for those with a time to relapse after initial ASCT of longer than 24 months. The overall survival after salvage ASCT was favorable excluding patients with the following factors: early relapse, poor PS, moderate/severe renal comorbidity, and progressive disease (p < 0.001). In conclusion, our results reinforced the evidence for encouraging salvage ASCT for eligible patients.

20 June 2018 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
SOShuki Oya
Shuki Oya
TMTsuyoshi Muta
Tsuyoshi Muta


1 January 2012 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TMTsuyoshi Muta
Tsuyoshi Muta
TNTakashi Nakaike
Takashi Nakaike
TFTomoaki Fujisaki
Tomoaki Fujisaki
TSTakeshi Shiraishi
Takeshi Shiraishi
KOKoichi Ohshima
Koichi Ohshima
A 76-year-old man suffered from swelling stoma for several weeks. A biopsy sample revealed the diffuse infiltration of large lymphoid cells which were positive for CD20, bcl-6, and MUM1. The patient was diagnosed with diffuse large B-cell lymphoma, with a non-germinal center B-cell pattern. A whole-body PET-CT scan revealed that the lymphoma was restricted to the stomal site. Bladder reconstruction was undertaken using the ileal conduit: this is the first reported case of lymphoma that developed primarily at the stoma. During the long-term maintenance after bladder reconstruction, clinicians should consider the possibility of lymphoma at the stomal site.

1 January 2018 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TMTsuyoshi Muta
Tsuyoshi Muta
TYTomoyasu Yoshihiro
Tomoyasu Yoshihiro
FJFumiaki Jinnouchi
Fumiaki Jinnouchi
KAKenichi Aoki
Kenichi Aoki
YKYu Kochi
Yu Kochi
KOKoichi Oshima
Koichi Oshima
A 64-year-old woman presented with generalized lymphadenopathy and systemic manifestations. The examination of a biopsy specimen revealed peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) expressing cytotoxic molecules. Umbilical cord blood transplantation was successful during a partial remission state after the administration of salvage chemotherapy. The donor-derived large granular lymphocytes started to increase as a result of cytomegalovirus reactivation. The fraction of natural killer (NK) cells expressing the NKG2C molecule accounted for one-third of the total lymphocytes for almost two years. We implicitly indicate the association between the persistence of donor-derived NKG2C+ NK cell-expansion and maintaining a complete remission in similar cases of aggressive PTCL-NOS.